Overview

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant. PURPOSE: This phase II trial is studying how well caspofungin acetate works as first-line treatment for aspergillosis in patients with hematologic cancer or in patients who have undergone a stem cell transplant.

Phase:

Phase 2

Details

Lead Sponsor:

European Organisation for Research and Treatment of Cancer - EORTC

Treatments:

Caspofungin
Echinocandins